Liprolog (insulin lispro)
- Region
- 🇪🇺 EU
- Active substance
- insulin lispro
- Company
- Eli Lilly Nederland B.V.
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Thu 26 Apr 2001
- EU approval
- Wed 01 Aug 2001
- Application
- EMEA/H/C/000393
- ATC
- A10AB04;A10AD04
- Official record
- www.ema.europa.eu
Indication
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilisation of diabetes mellitus.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Bysumlog Authorised · Sandoz GmbH
- 🇪🇺 Lyumjev (previously Liumjev) Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Humalog Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Insulin lispro Sanofi Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Liprolog Withdrawn · Eli Lilly and Company Limited
Follow Liprolog
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.